Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke

Circulation

Volumn 107, Issue 4, 2003, Pages 598-603

  Montaner, Joan ^a   Molina, Carlos A ^a   Monasterio, Jasone ^a   Abilleira, Sonia ^a   Arenillas, Juan F ^a   Ribó, Marc ^a   Quintana, Manolo ^a   Alvarez Sabín, José ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Hemorrhage; Metalloproteinases; Stroke; Thrombolysis

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN SCINTISCANNING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENZYME ASSAY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY; NEUROLOGICAL COMPLICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAFETY; STROKE;

ADULT; AGED; AGED, 80 AND OVER; BRAIN; CEREBROVASCULAR ACCIDENT; DISEASE PROGRESSION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; IMMUNOASSAY; INFARCTION, MIDDLE CEREBRAL ARTERY; INTRACRANIAL HEMORRHAGES; LOGISTIC MODELS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0037418038     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000046451.38849.90     Document Type: Article

References (31)

1. The National Institutes of Neurological Disorders, and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990;6:121-125.
3. Mun-Bryce S, Rosenberg GA. Matrix metalloproteinases in cerebrovascular disease. J Cerebral Blood Flow Metab. 1998;18;1163-1172.
4. Rosenberg GA, Mun-Bryce S, Wesley M, et al. Collagenase-induced intracerebral hemorrhage in the rat. Stroke. 1990;21:801-807.
5. Heo JH, Lucero J, Abumiya T, et al. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab. 1999;19:624-633.
6. Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (fissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke. 2000;31:3034-3040.
7. Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after focal ischemia in rats. Stroke. 2002;33:831-836.
8. Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. Stroke. 1993;24:35-41.
9. Brott TG, Haley EC, Levy DE, et al. Urgent therapy for stroke, part I: pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992;23:632-640.
10. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 1995; 274:1017-1025.
11. Pessin M, del Zoppo G, Estol C. Thrombolytic agents in the treatment of stroke. Clin Neuropharmacol. 1990;13:271-289.
12. von Kummer R, Allen KL, Holle R, et al. Acute stroke: usefulness of early CT findings before thrombolytic therapy. Radiology. 1997;205:327-333.
13. Berger C, Fiorelli M, Steiner T, et al. Hemorrhagic transformation of ischemic brain tissue: asymptomatic of symptomatic? Stroke. 2001;32:1330-1335.
14. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke. 1997;28:2109-2118.
15. Lanue V, von Kummer RR, Muller A, et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australian Acute Stroke Study (ECASS II). Stroke. 2001;32:438-441.
16. Molina CA, Alvarez-Sabin, J, Montaner J, et al. Thrombolysis-related hemorrhagic infarction: a marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke. 2002;33:1551-1556.
17. Montaner J, Alvarez-Sabín J, Molina C, et al. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke. 2001;32:1759-1766.
18. Hamann GF, Okada Y, Fitridge R, et al. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke. 1995;26:2120-2126.
19. Hamman GF, Okada Y, del Zoppo GJ. Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion. J Cerebral Blood Flow Metab. 1996;16:1373-1378.
20. Romanic AM, White RF, Arleth AJ, et al. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats. Inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke. 1998;29:1020-1030.
21. Ogata J, Masuda J, Yutani C, et al. Microvascular leukocyte plugging in evolving brain infarction in humans. In: Yamaguchi T, Mori E, Minematsu K, del Zoppo GJ, eds. Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo, Japan: Springer-Verlag; 1995:311-314.
22. Kano T, Katayama Y, Tejima E, et al. Hemorrhagic transformation after fibrinolytic therapy with tissue plasminogen activator in a rat thromboembolic model of stroke. Brain Res. 2000;854:245-248.
23. Weiss SJ, Peppin GJ. Collagenolyfic metalloenzymes of the human neutrophil. Biochem Pharmacol. 1986;35:3189-3197.
24. Rosenberg GA, Kornfeld M, Estrada E, et al. TIMP-2 reduces protelytic opening of blood-brain barrier by type IV collagenase. Brain Research. 1992;576:203-207.
25. Montaner J, Alvarez-Sabín J, Molina C, et al. Matrix metalloproteinase (MMP-9) expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke. 2001;32:2762-2767.
26. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem. 1997;378:151-160.
27. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, et al. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem. 1999; 274:13066-13076.
28. Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation. 2002;105:1679-1685.
29. Demchuk AM, Morgenstern LB, Krieger DW, et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke. 1999;30:34-39.
30. Uemura S, Matsushita H, Li W, et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res. 2001;88:1291-1298.
31. Massengale JL, Gasche Y, Chan PH. Carbohydrate source influences gelafinase production by mouse astrocytes in vitro. Glia. 2002;38:240-245.